metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mBC - Triple negative (TNBC) - 1st Line (L1) breast cancer - triple negative breast cancer - triple negative metastatic mBC - Triple negative (TNBC) - 1st Line (L1)
versus nab-paclitaxel, placebo
	toripalimab
	TORCHLIGHT, 2024 Nat Med 2024; 30:249-256-. NCT04085276	RCT	mBC - Triple negative (TNBC) - 1st Line (L1)	toripalimab and nab-paclitaxel	placebo and nab-P	Patients aged at least 18 years with histologically confirmed TNBC, previously untreated or no more than one previous systemic chemotherapy regimen for stage IV or locally advanced TNBC that is not amenable to surgery	353 / 178	low	inconclusive	suggested 31 % decrease in deaths (OS) suggested 23 % decrease in progression or deaths (PFS) (PE) statistically significant 73 % increase in SAE (grade 3-4)
	TORCHLIGHT PDL 1 positive population, 2024 Nat Med 2024; 30:249-256-. NCT04085276	RCT	mBC - Triple negative (TNBC) - 1st Line (L1)	toripalimab and nab-paclitaxel	placebo and nab-P	Patients aged at least 18 years with histologically confirmed TNBC, previously untreated or no more than one previous systemic chemotherapy regimen for stage IV or locally advanced TNBC that is not amenable to surgery	200 / 100	low	conclusif	suggested 38 % decrease in deaths (OS) demonstrated 35 % decrease in progression or deaths (PFS) (PE) The addition of toripalimab to nab-P provided a significant improvement in PFS for PD-L1-positive patients with metastatic or recurrent TNBC with an acceptable safety profile.

mBC - Triple negative (TNBC) - 1st Line (L1) breast cancer - triple negative breast cancer - triple negative metastatic mBC - Triple negative (TNBC) - 1st Line (L1)

versus nab-paclitaxel, placebo

toripalimab